CAS NO: | 867021-83-8 |
包装 | 价格(元) |
500ug | 电议 |
1mg | 电议 |
Physical Appearance | White lyophilised solid |
Storage | Store at -20°C |
M.Wt | 2645.13 |
Cas No. | 867021-83-8 |
Formula | C119H206N32O35 |
Solubility | insoluble in DMSO; insoluble in EtOH; ≥15 mg/mL in H2O |
Canonical SMILES | CC[C@]([C@@](/N=C(O)/[C@](/N=C(O)/C/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/C/N=C(O)/[C@](/N=C(O)/[C@]1([H])CCCN1C([C@](/N=C(O)/[C@]2([H])CCCN2C([C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/ |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
Colivelin is a brain-penetrant neuroprotective peptide, exhibiting potent long-term capacity against Aβ deposition, synaptic plasticity deficits, and neuronal apoptosis in neurodegenerative disease. Moreover, Colivelin is an activator of STAT3, which can rescue ischemic neuronal death and axonal remodeling by activating JAK/STAT3 signaling. Thus, Colivelin has the potential for the treatment of Alzheimer’s disease and ischemic brain injury.
References:
1. Zhao H, Feng Y, Wei C, et al. Colivelin Rescues Ischemic Neuron and Axons Involving JAK/STAT3 Signaling Pathway. Neuroscience, 2019, 416: 198-206.
2. Chiba T, Yamada M, Hashimoto Y, et al. Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insultsin vitroandin vivo. The Journal of Neuroscience, 2005, 25(44): 10252-10261.
Cell experiment:[2] | |
Cell lines | Mouse primary cortical neurons (PCNs) |
Reaction Conditions | 100 aM, 1 fM, 10 fM, 100 fM, 1 pM, 10 pM, 100 pM, 1 nM, 10 nM, or 100 nM Colivelin for 16 h incubation |
Applications | Colivelin at a concentration of 100 fM completely suppressed neuronal death induced by Aβ1-43. Colivelin was a femtomolar-acting bioactive peptide at least as potent as ADNFin vitro. Furthermore, Colivelin did not lose its neuroprotective activity even at higher concentrations. |
Animal experiment:[1] | |
Animal models | Male C57BL/6 mice, 10 ~ 12 wk of age |
Dosage form | 1 mg/kg Once daily by intraperitoneal injection for 6 days |
Applications | Colivelin treatment resulted in improved motor and cognitive function over time (from day 1 to day 14 post ischemia and reperfusion), as shown by performance of mNSS, rotarod, and corner turning test. It also reduced lesion volume and improved neurological deficits after middle cerebral artery occlusion. |
Note | The technical data provided above is for reference only. |
References: 1. Zhao H, Feng Y, Wei C, et al. Colivelin Rescues Ischemic Neuron and Axons Involving JAK/STAT3 Signaling Pathway. Neuroscience, 2019, 416: 198-206. 2. Chiba T, Yamada M, Hashimoto Y, et al. Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insultsin vitroandin vitro. The Journal of Neuroscience, 2005, 25(44): 10252-10261. |